Sotatercept

Sotatercept
Clinical data
Trade namesWinrevair
Other namesACE-011, MK-7962, sotatercept-csrk
AHFS/Drugs.comMonograph
License data
Routes of
administration		Subcutaneous
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC3448H5264N920O1058S42
Molar mass77879.94 g·mol−1

Sotatercept, sold under the brand name Winrevair is a medication used for the treatment of pulmonary arterial hypertension.[1] It is an activin signaling inhibitor,[1] based on the extracellular domain of the activin type 2 receptor expressed as a recombinant fusion protein with immunoglobulin Fc domain (ACTRIIA-Fc).[4] It is given by subcutaneous injection.[1]

The most common side effects include headache, epistaxis (nosebleed), rash, telangiectasia (spider veins), diarrhea, dizziness, and erythema (redness of the skin).[1][5]

Sotatercept was approved for medical use in the United States in March 2024,[1][6][7] and in the European Union in August 2024.[2][3][8]

  1. ^ a b c d e f "Winrevair- sotatercept-csrk kit". DailyMed. 26 March 2024. Archived from the original on 25 April 2024. Retrieved 25 April 2024.
  2. ^ a b Cite error: The named reference Winrevair EPAR was invoked but never defined (see the help page).
  3. ^ a b Cite error: The named reference Winrevair PI was invoked but never defined (see the help page).
  4. ^ Doggrell, Sheila A (July 2023). "Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?". Expert Opinion on Biological Therapy. 23 (7): 589–593. doi:10.1080/14712598.2023.2221784. hdl:10072/423493. PMID 37269300.
  5. ^ Cite error: The named reference Winrevair FDA snapshot was invoked but never defined (see the help page).
  6. ^ "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 29 April 2024. Archived from the original on 30 April 2024. Retrieved 30 April 2024.
  7. ^ "FDA Approves Merck's Winrevair (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)" (Press release). Merck. 27 March 2024. Archived from the original on 27 March 2024. Retrieved 27 March 2024 – via Business Wire.
  8. ^ Cite error: The named reference Merck PR 20240826 was invoked but never defined (see the help page).